Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Lincoff

Showing results (41-50 of 116) with videos related to

Pageof 12
Sort By:
European Heart Journal|July 2, 2002
Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT TrialW-C Chang, R A Harrington, M L Simoons, et al.
Journal of the American College of Cardiology|March 25, 2000
Abciximab reduces mortality in diabetics following percutaneous coronary interventionD L Bhatt, S P Marso, A M Lincoff, et al.
European Heart Journal|November 1, 1995
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptorE M Ohman, R A Harrington, A M Lincoff, et al.
Journal of the American College of Cardiology|November 11, 1998
The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctionsS R Steinhubl, M S Lauer, D P Mukherjee, et al.
Circulation|February 22, 2001
Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trialsD P Chew, D L Bhatt, A M Lincoff, et al.
Journal of the American College of Cardiology|December 1, 1993
Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study GroupA M Lincoff, R M Califf, S G Ellis, et al.
Journal of the American College of Cardiology|April 8, 1999
Comparing physician-specific two-year patient outcomes after coronary angiography: methodologic issues and resultsS G Ellis, D Miller, T F Keys, et al.
Circulation|November 28, 2001
beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme riseS G Ellis, S J Brener, A M Lincoff, et al.
Journal of the American College of Cardiology|November 20, 1998
Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor BlockadeS G Ellis, A M Lincoff, D Miller, et al.
American Heart Journal|January 30, 1999
Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC InvestigatorsM C Thel, R M Califf, J E Tcheng, et al.
Pageof 12

Showing results (41-50 of 116) with videos related to

Sort By:
Pageof 12
European Heart Journal|July 2, 2002
Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT TrialW-C Chang, R A Harrington, M L Simoons, et al.
Journal of the American College of Cardiology|March 25, 2000
Abciximab reduces mortality in diabetics following percutaneous coronary interventionD L Bhatt, S P Marso, A M Lincoff, et al.
European Heart Journal|November 1, 1995
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptorE M Ohman, R A Harrington, A M Lincoff, et al.
Journal of the American College of Cardiology|November 11, 1998
The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctionsS R Steinhubl, M S Lauer, D P Mukherjee, et al.
Circulation|February 22, 2001
Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trialsD P Chew, D L Bhatt, A M Lincoff, et al.
Journal of the American College of Cardiology|December 1, 1993
Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study GroupA M Lincoff, R M Califf, S G Ellis, et al.
Journal of the American College of Cardiology|April 8, 1999
Comparing physician-specific two-year patient outcomes after coronary angiography: methodologic issues and resultsS G Ellis, D Miller, T F Keys, et al.
Circulation|November 28, 2001
beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme riseS G Ellis, S J Brener, A M Lincoff, et al.
Journal of the American College of Cardiology|November 20, 1998
Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor BlockadeS G Ellis, A M Lincoff, D Miller, et al.
American Heart Journal|January 30, 1999
Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC InvestigatorsM C Thel, R M Califf, J E Tcheng, et al.
Pageof 12